Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
RSLS was the Nasdaq ticker symbol for ReShape Lifesciences Inc., a physician-led weight loss and metabolic health-solutions company focused on device-based treatments for obesity and metabolic disease. News flow around RSLS has covered both the company e2 80 99s product developments in surgical and medical instruments and its major corporate transactions, including a reverse merger and asset sale.
ReShape Lifesciences frequently announced updates related to its obesity treatment technologies. These included communications about the FDA-approved Lap-Band ae System and Lap-Band ae 2.0 FLEX, the Obalon ae swallowable intragastric balloon technology, and the investigational Diabetes Bloc-Stim Neuromodulation ae (DBSN ae) system for type 2 diabetes and metabolic disorders. The company also issued news about its intellectual property, such as the issuance of a U.S. patent titled e2 80 9cIntragastric Device e2 80 9d covering a swallowable, degradable intragastric balloon system.
In addition to product and IP announcements, RSLS-related news has focused heavily on strategic and financial events. ReShape Lifesciences disclosed a merger agreement with Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, and later reported shareholder approvals, Nasdaq listing approvals, and completion of the merger. Following the closing on August 15, 2025, the public company was renamed Vyome Holdings, Inc. and began trading under the symbol HIND. News items also addressed the sale of substantially all of ReShape e2 80 99s assets to an affiliate of Biorad Medisys, reverse stock split approvals and implementation, cost reduction measures, and Nasdaq compliance updates.
Investors and observers using this RSLS news page can review historical coverage of ReShape Lifesciences e2 80 99 product announcements, patent milestones, corporate governance changes, shareholder meetings, merger progress with Vyome Therapeutics, and the asset sale to Biorad Medisys. This context helps explain how the former RSLS-listed company transitioned into Vyome Holdings, Inc. and why the stock now trades under the HIND symbol on The Nasdaq Capital Market.
ReShape Lifesciences (Nasdaq: RSLS) has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Ansari brings over 30 years of experience in developing sales initiatives within the medical device industry, having previously held key roles at Enteromedics, Johnson & Johnson, and Medtronic. His leadership is expected to enhance sales growth for the Lap-Band® and strengthen ReShape's market presence globally. The Lap-Band® has successfully helped over one million patients achieve weight loss over the past two decades.
ReShape Lifesciences (RSLS) reported a 19% sequential revenue increase for Q2 2022, reaching $2.9 million, following decreased COVID-19 restrictions. The company secured FDA clearance for the GIBI HD calibration tube and appointed new CEO Paul F. Hickey, enhancing its leadership. Financially, RSLS experienced a decline in gross profit to $1.9 million, with adjusted EBITDA losses widening to $7.8 million. Expenses surged due to a robust DTC marketing campaign, though cash reserves of $11.5 million strengthen its position into 2023. The outlook remains cautiously optimistic as sales momentum builds.
ReShape Lifesciences (Nasdaq: RSLS) will report its Q2 2022 financial results on August 15, 2022, after-market. The company specializes in weight loss and metabolic health solutions. A conference call will be held on the same day at 4:30 pm ET, with access through their website. ReShape offers products like the FDA-approved Lap-Band Program and the investigational ReShape Vest System. Their services include reshapecare, a virtual weight-management program, and the ReShape Marketplace, an online wellness product collection.
ReShape Lifesciences (Nasdaq: RSLS) has received FDA 510(k) clearance for its Gastro Intestinal Balloon Indicator (GIBI HD™) calibration tube, designed for gastric and bariatric procedures. The GIBI HD™ will come in three sizes (32, 36, and 40 Fr) and aims to enhance surgical visibility and safety. U.S. commercial sales are set to commence in September 2022. The company plans to showcase the product at the IFSO 2022 World Congress in Miami. This advancement is part of ReShape's broader strategy to innovate weight loss solutions.
ReShape Lifesciences (Nasdaq: RSLS) has appointed Paul F. Hickey as its new President and CEO, effective August 15, 2022. He replaces Bart Bandy, who has left the company. Hickey brings over 25 years of medical device commercialization experience, notably serving as SVP of Marketing and Reimbursement at EnteroMedics, the predecessor to ReShape. Under his leadership, the company aims to advance its weight loss solutions, including the Lap-Band Program and reshapecare Virtual Health Coaching. Dan W. Gladney, chair of the Board, will take on a more active role as Executive Chair to support Hickey.
ReShape Lifesciences Inc. (Nasdaq: RSLS) announced a warrant exercise agreement enabling an existing investor to purchase up to 3.7 million shares of common stock for approximately $2.5 million. The exercise price was reduced to $0.6665 per share, aligning with the recent closing price. New warrants for the same number of shares will be issued, having a seven-and-a-half-year term. The funds from this agreement will extend the company's cash runway through 2023 and support its marketing initiatives, increasing demand for its Lap-Band procedures.
ReShape Lifesciences (Nasdaq: RSLS) has announced a partnership with OpenLoop to provide a nationwide, physician-led telehealth solution called reshapecare™. This program offers virtual weight loss coaching through video-based counseling with licensed clinicians and board-certified health coaches, aiming to help patients improve their health goals. reshapecare™ may be covered by major insurance plans for up to 26 visits annually. The collaboration is expected to enhance patient access and outcomes in obesity management.
ReShape Lifesciences reported Q1 2022 revenues of $2.4 million, a 24.2% decline from Q1 2021, primarily due to the COVID-19 Omicron variant impacting bariatric procedures. However, March 2022 revenues surpassed January and February combined, indicating recovery. The company attributes this growth to a successful direct-to-consumer (DTC) marketing campaign. Gross profit decreased to $1.2 million, with a margin of 50%. Sales and marketing expenses soared by 276.6% to $4.7 million. Non-GAAP adjusted EBITDA loss widened to $7.1 million, reflecting increased marketing investment.
Summary not available.
ReShape Lifesciences (Nasdaq: RSLS) announced it will release its first-quarter financial results for 2022 on May 23, 2022, before the market opens. The company will also provide a corporate update during a webcast scheduled for 8:30 am ET on the same day. ReShape Lifesciences focuses on weight loss and metabolic health solutions, offering various FDA-approved and investigational products. Investors can access the results and the accompanying webcast link on the company’s website.
FAQ
What is the current stock price of ReShape Lifesciences (RSLS)?
What is the market cap of ReShape Lifesciences (RSLS)?
